| UHC Medicare Advantage | Cosmetic and Reconstructive Procedures – Medicare Advantage Medical Policy | 2025-10-01 |
| UHC Medicare Advantage | Durable Medical Equipment (DME), Prosthetics, Orthotics (Non-Foot Orthotics), Nutritional Therapy, and Medical Supplies Grid – Medicare Advantage Medical Policy | 2025-10-01 |
| UHC Medicare Advantage | Percutaneous Coronary Interventions – Medicare Advantage Medical Policy | 2025-10-01 |
| UHC Medicare Advantage | Percutaneous Ventricular Assist Device – Medicare Advantage Medical Policy | 2025-10-01 |
| UHC Medicare Advantage | Uterine Services and Procedures – Medicare Advantage Medical Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Antiemetics for Oncology – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Cosentyx® (Secukinumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Encelto™ (Revakinagene Taroretcel-Lwey) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Ilumya® (Tildrakizumab-Asmn) – Commercial Medical Benefit Drug Policy | 2025-10-01 |
| UHC UMR Medical and Drug | Lemtrada® (Alemtuzumab) – Commercial Medical Benefit Drug Policy | 2025-10-01 |